Table 3 Primary samples derived of myeloma patients
Patient# | Sample# | Age | Gender | Ig subtype | Stage | Therapies | FISH |
|---|---|---|---|---|---|---|---|
1 | 1 | 64 | f | IgG lambda | III A | None | Tri9q |
2 | 64 | f | IgG lambda | III A | 3× RADa | Tri9q | |
2 | 3 | 50 | m | IgG kappa | III A | Dexab 4× RAD 2× HD-Melc Lend | Normal |
3 | 4 | 73 | m | IgG kappa | I A | None | Hyperdiploide CMYC-Rearrangement |
4 | 5 | 58 | f | IgG lambda | I A | None | Amp1q21 |
5 | 6 | 78 | f | IgG lambda | II A | None | – |
6 | 7 | 72 | m | IgG kappa | I A | None | – |
7 | 8 | 43 | m | IgA kappa | III A | None | Hyperdiploid |
8 | 9 | 68 | f | IgG kappa | III A | None | Hyperdiploid |
9 | 10 | 49 | f | IgG kappa | III A | None | Tri9q |
10 | 11 | 61 | m | Kappa LC | III B | 3× ID > 2× HD-Mel; VRCDe > HD-Mel; VRCD | Normal |
11 | 12 | 67 | m | IgG lambda | II A | None | Hyperdiploid |
12 | 13 | 62 | m | Kappa LC | II A | None | Tri1q |
